107 related articles for article (PubMed ID: 6344993)
21. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
22. [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
Sauter C
Schweiz Med Wochenschr; 1994 Oct; 124(43):1879-81. PubMed ID: 7973513
[No Abstract] [Full Text] [Related]
23. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
24. Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.
Tormey D; Gelman R; Falkson G
Am J Clin Oncol; 1983 Feb; 6(1):1-18. PubMed ID: 6340458
[No Abstract] [Full Text] [Related]
25. [Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
Tamura H; Kojima M; Kobayashi H; Ando J; Oka S; Fujisaki M; Wada N; Imoto S; Ikeda T
Gan To Kagaku Ryoho; 2000 Jul; 27(7):993-1002. PubMed ID: 10925684
[TBL] [Abstract][Full Text] [Related]
26. [Recent advance in adjuvant therapy for breast cancer].
Shimizu C; Watanabe T
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
[TBL] [Abstract][Full Text] [Related]
27. [5 years' results of a CMF protocol (methotrexate, cyclophosphamide, fluorouracil) of adjuvant chemotherapy in breast cancers].
Horner-Vallet D; Cappelaere P; Delobelle A; Depadt G; Madelain M; Demaille A
LARC Med; 1984 Nov; 4(9):532-40. PubMed ID: 6549038
[No Abstract] [Full Text] [Related]
28. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
29. Commentary on PBT-1 study of high-dose consolidation versus standard therapy in metastatic breast cancer.
Livingston R; Crowley J
J Clin Oncol; 1999 Nov; 17(11 Suppl):22-4. PubMed ID: 10630257
[No Abstract] [Full Text] [Related]
30. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
[TBL] [Abstract][Full Text] [Related]
31. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
[TBL] [Abstract][Full Text] [Related]
33. [Adjuvant therapy of breast cancer. 1: Cytostatic therapy].
Possinger K; Sauer HJ; Wilmanns W
Fortschr Med; 1986 Aug; 104(29):552-5. PubMed ID: 3758881
[No Abstract] [Full Text] [Related]
34. [Chemotherapy in curable breast cancer].
Seradour B; Thomas M
J Gynecol Obstet Biol Reprod (Paris); 1978 Mar; 7(2):175-82. PubMed ID: 353124
[No Abstract] [Full Text] [Related]
35. [Combined chemotherapy in metastatic breast cancer: predictive value of dose levels and performance status].
Brufman G; Sulkes A; Fuks Z; Biran S
Harefuah; 1986 Jul; 111(1-2):24-6. PubMed ID: 3781373
[No Abstract] [Full Text] [Related]
36. A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
Howell A; Rubens RD; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Hayward JL; Knight RK; Bulbrook RD
Recent Results Cancer Res; 1984; 96():74-89. PubMed ID: 6396780
[No Abstract] [Full Text] [Related]
37. Are surgical adjuvant trials altering the course of breast cancer?
Bonadonna G; Valagussa P; Rossi A; Zucali R; Tancini G; Bajetta E; Brambilla C; De Lena M; Di Fronzo G; Banfi A; Rilke F; Veronesi U
Semin Oncol; 1978 Dec; 5(4):450-64. PubMed ID: 366757
[No Abstract] [Full Text] [Related]
38. Adjuvant chemotherapy for early breast cancer.
Smith IE
Br Med J (Clin Res Ed); 1983 Aug; 287(6389):379-80. PubMed ID: 6409315
[No Abstract] [Full Text] [Related]
39. The effect of chemotherapy on the morphology of human breast carcinoma.
Close PM; Tiltman AJ; Hacking EA
S Afr Med J; 1987 Jul; 72(2):103-6. PubMed ID: 3039671
[TBL] [Abstract][Full Text] [Related]
40. Dose intensity in chemotherapy of metastatic breast cancer.
J Clin Oncol; 1985 Jun; 3(6):889-91. PubMed ID: 3891924
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
